If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Pain Interference Improves More With Denosumab Than Zoledronic Acid in Patients With Advanced Breast Cancer: Presented at SABCS By Jill Stein SAN ANTONIO, Tex -- December 12, 2010 -- Patients with breast cancer with bone metastases report greater improvement in the extent to which pain interferes with their daily functioning when treated with denosumab than with zoledronic acid, according to a study presented here at the 33rd annual San Antonio Breast Cancer Symposium (SABCS). Charles S. Cleeland, PhD, University of Texas M. D. Cancer Center, Houston, Texas, and colleagues elsewhere examined differences between the 2 treatments in patient-reported pain interference with daily functioning using data from a phase 3 trial that compared denosumab with zoledronic acid in women with advanced breast cancer and bone metastases. Bone metastases occur in up to 75% of patients with advanced breast cancer and are frequently associated with skeletal-related events (including spinal cord compression, pathologic fracture, surgery or radiation to bone), as well as severe pain. In the trial, patients completed the 11-point Brief Pain Inventory-Short Form (BPI-SF) to assess pain interference with general activity, walking, work, mood enjoyment of life, relations with others and sleep, and to assess pain severity. The analysis included 1,018 patients treated with denosumab and 1,011 patients treated with zoledronic acid. Results showed that time to improvement in pain interference with activity (PIWA) tended to occur more rapidly with denosumab than with zoledronic acid (a median of 70 vs 86 days; P =.09). Also, time to worsening PIWA tended to tended to be longer with denosumab than with zoledronic acid (median of 394 vs 310 days; P =.13). In women with no pain or only mild pain at enrollment, denosumab showed a trend for shorter time to improvement in PIWA and a longer time to worsening PIWA. Also, a shift in analgesic use from no or low analgesics to strong opioids occurred in fewer patients treated with denosumab. Funding for this study was provided by Amgen Inc. [Presentation title: Comparing the Effects of Denosumab and Zoledronic Acid on Pain Interference With Daily Functioning in a Randomized Phase 3 Trial of Patients With Breast Cancer and Bone Metastases. Abstract P1-13-01]
|
